Nanodendrimers in Antiepileptic Drug Delivery: Current Progress and Future Perspectives

Read full text Summarise with VIRAT
Authors: Dr. Neeraj Jain, Dr. Neelam Jain, Ankeeta, Prakhar Srivastava, Pragati Mishra, Suraj Neupane, Palak Chaurasia, Pawni Chaurasia, Ankita Tripathi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In terms of public health, central nervous system (CNS) illnesses play a critical role. One of the most frequent CNS illnesses is epilepsy. Epilepsy is a chronic condition that causes significant morbidity and death. Many individuals worldwide suffer from epilepsy, and the reasons of this condition are yet unknown. Epilepsy affects roughly 50 million individuals worldwide. Antiepileptic medications are often used in the treatment of epilepsy, however the problem with these treatments is the development of drug resistance, and antiepileptic drugs may be taken orally or intravenously. These therapies, however, are not always successful. Drugs used to treat epilepsy, on the other hand, must be supplied properly and securely in order to preserve the brain. As a result, novel delivery methods are required to administer medications at doses found to have great therapeutic effectiveness in epilepsy while minimising negative effects. In light of this knowledge, new therapeutic options are required. Dendrimers are one such therapeutic option which can help to active site specific and more successful results. Hence, in present article we have summarized the epilepsy condition, dendrimers and its use in epilepsy in brief.

Fields of Study & Subjects

Dendrimers and Hyperbranched Polymers Advanced Drug Delivery Systems Nanoparticle-Based Drug Delivery

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN